Patent US5154913A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5154913A Expired / Lapsed US ⏱️ 0.0 years remaining

Radioiodinated benzamines method of their use as radioimaging agents

Assignee: Vanderbilt University
•
Filing: 1991-05-28
•
Granted: 1992-10-13
•
Expires: 2011-05-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D-2 receptor in the mammalian brain. The substituted benzamides and their racemic mixtures or their optically resolved enantiomers can be made by reacting a trialyltin substituted benzamide with an acid in the presence of radioactive iodine, generated by in situ oxidation of an appropriate iodide nuclide salt.

Inventors

  • 👤 Tomas De Paulis
  • 👤 Robert M. Kessler
  • 👤 Howard E. Smith
  • 👤 Aaron Janowsky
  • 👤 Jeffrey A. Clanton

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 21:25
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/04; C07D207/08; C07D207/09

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinylmethyl]-5-iodo-2-methoxybenzamide.
Claim 2
Dependent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinylmethyl]-5-iodo-2-methoxybenzamide.
Claim 3
Dependent Claim 3 words
[ 123 I](R)-N-[(1-4fluorobenzyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxybenzamide
Claim 4
Dependent Claim 3 words
[ 123 I](R)-N-[(1-4fluorobenzyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxybenzamide
Claim 5
Dependent Claim 3 words
[ 123 I](S)-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-chloro-3-iodo-6-methoxysalicylamide.
Claim 6
Dependent Claim 3 words
[ 123 I](S)-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-chloro-3-iodo-6-methoxysalicylamide.
Claim 7
Dependent Claim 3 words
[ 123 I](R)-N-[1-(4-fluorobenzyl)-2-pyrrolidinyl)methyl]5-iodo-2,3-dimethoxybenzamide.
Claim 8
Dependent Claim 3 words
[ 123 I](R)-N-[1-(4-fluorobenzyl)-2-pyrrolidinyl)methyl]5-iodo-2,3-dimethoxybenzamide.
Claim 9
Dependent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenzamide.
Claim 10
Dependent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenzamide.
Claim 11
Dependent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-5,6-dimethoxysalicylamide.
Claim 12
Dependent Claim 3 words
[ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-5,6-dimethoxysalicylamide.
Claim 13
Independent Claim 43 words
A method of radioimaging a human brain comprising the steps of: (a) systematically applying a radioiodinated substituted benzamine selected from the group consisting of [ 123 I](S)-N-[(1-ethyl-2-pyrrolidinylmethyl]-5-iodo-2-methoxy-benzamide; ( 123 I](R)-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxy-benzamide; [ 123 I](S)-5-chloro-N-[1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-6-methoxysalicylamide; [ 123 I](R)-N-[(1-(4-fluorophenyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxybenzamide; and [ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-5,6-dimethoxysalicylamide; [ 123 I](R)-N-[(1-ethyl-w-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxy-benzamide.
Claim 14
Independent Claim 43 words
A method of radioimaging a human brain comprising the steps of: (a) systematically applying a radioiodinated substituted benzamine selected from the group consisting of [ 123 I](S)-N-[(1-ethyl-2-pyrrolidinylmethyl]-5-iodo-2-methoxy-benzamide; ( 123 I](R)-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxy-benzamide; [ 123 I](S)-5-chloro-N-[1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-6-methoxysalicylamide; [ 123 I](R)-N-[(1-(4-fluorophenyl-2-pyrrolidinyl)methyl]-5-iodo-2-methoxybenzamide; and [ 123 I](S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-iodo-5,6-dimethoxysalicylamide; [ 123 I](R)-N-[(1-ethyl-w-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxy-benzamide.

References Cited (Backward Citations)

US3342826A Cited
US3591634A Cited
US4673686A Cited
US4232037A Cited
JPS55130957A Cited
EP0105599A1 Cited
US4574079A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-10-13 1996-04-13 1996-10-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-10-13 2000-04-13 2000-10-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-10-13 2004-04-13 2004-10-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag